"We are committed to providing up-to-date, useful and clear reviews of the most important perspectives in oncology that have been recently identified," explained Editor, Paul Sondel. "Each issue of Update on Cancer Therapeutics reflects a spectrum of reviews presenting recent data, conclusions and recommendations that advance our understanding of anti-cancer drugs, specific malignancies and immunotherapy-host responses," added Editor Richard Schilsky. "This format also enables user-friendly focused summaries of newer concepts and practices that complement both standard textbook chapters as well as initial reports of new findings," noted Editor Giuseppe Giaccone.
Subscribers will have full access to each issue as well as articles in press on the journal's website, www.updateoncancer.com. Update on Cancer Therapeutics will also be accessible through Elsevier's online database, ScienceDirect http://www.sciencedirect.com/, the world's largest electronic collection of science, technology and medicine full text and bibliographic information.
About Elsevier
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier's 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect (http://www.sciencedirect.com/), MD Consult (http://www.mdconsult.com/), Scopus (http://www.info.scopus.com/), bibliographic databases, and online reference works.
Elsevier (http://www.elsevier.com/) is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc (http://www.reedelsevier.com/), a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).